恩替卡韦联合干扰素治疗慢性乙型肝炎疗效观察

《恩替卡韦联合干扰素治疗慢性乙型肝炎疗效观察》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、恩替卡韦联合干扰素治疗慢性乙型肝炎疗效观察［摘要］目的观察恩替卡韦联合干扰素治疗慢性乙型肝炎的临床疗效。方法选择2008年1月〜2016年1月我院收治的轻中度慢性乙型肝炎患者106例，根据治疗方法不同分为联合组50例与对照组56例，两组均予甘利欣、能量合剂、维生素、促肝细胞生长素等常规护肝治疗，其中联合组加用恩替卡韦联合干扰素a-2b治疗，比较两组患者治疗后的HBV-DNA转阴率及HBeAg血清转换率及两组患者肝功能指标AST、ALT及TBiL水平的变化。结果联合组治疗后的HBV-DNA转阴率、HBeAg血清转换率分别显著高于对照组，组间比较差异具有显著性。两组患者治疗前的AST、AL

2、T及TBiL水平组间比较无统计学差异;治疗后，两组患者的AST、ALT及TBiL水平显著降低；且联合组患者治疗后AST、ALT及TBiL水平显著低于对照组，组间比较差异具有显著性。结论恩替卡韦联合干扰素治疗慢性乙型肝炎疗效确切，可以显著改善肝功能，提高HBV-DNA转阴率。［关键词］慢性乙型肝炎；恩替卡韦；干扰素；肝功能［中图分类号］R512.62［文献标识码］B［文章编号］1673-970113-0108-03[Abstract]ObjectiveToobservetheclinicalefficacyofentecavircombinedwithinterferoninthetre

3、atmentofchronichepatitisB.Methods106patientswithmildtomoderatechronichepatitisBfromJanuary2008toJanuary2016inourhospitalweredividedintocombinedgroupaccordingtothedifferenttreatmentmethods，50casesinthecombinedgroupand56casesinthecontrolgroup，twogroupsweretreatedwithDiammoniumGlycyrrhizinate，energ

4、ymixture，vitamin,pHGFandotherconventionalliverprotectivetreatment,thecombinedgroupwastreatedwithentecavircombinedwithinterferontreatment,aftertreatment，HBV-DNAnegativerateandHBeAgseroconversionrateswerecomparedbetweentwogroups，andtheliverfunctionindexesofAST,ALTandTBiLlevelswerecomparedbetweentw

5、ogroups.ResultsTheHBV-DNAnegativeconversionrateandHBeAgseroconversionrateinthecombinedgroupweresignificantlyhigherthaninthecontrolgroup，andthedifferencewassignificant.TherewasnostatisticaldifferencebetweenAST，ALTandTBiLlevelsbetweentwogroupsofpatientsbeforetreatment;aftertreatment,twogroupsofpat

6、ientswithAST，ALTandTBiLweresignificantlydecreased；andtheAST，ALTandTBiLlevelsofjointgroupofpatientsaftertreatmentweresignificantlylowerthanthecontrolgroup，thedifferencewassignificantbetweentwogroups.ConclusionEntecavircombinedwithinterferoninthetreatmentofchronichepatitisbcurativehassignificantef

7、fect，cansignificantlyimprovetheliverfunction,improveHBV-DNAnegativerate.［Keywords］ChronichepatitisB；Entecavir；Interferon；Liverfunction慢性乙型肝炎令榱俅采铣＜令的传染性疾病之一，由于乙肝病毒长期存在且不断复制，可显著增加肝癌及肝硬化的发病风险，对患者的生命健康造成严重威胁［1］。目前临床治疗慢性乙型肝炎的常用药物